Literature DB >> 16005135

Antidepressant action of agomelatine (S 20098) in a transgenic mouse model.

Nicholas Barden1, Eric Shink, Michel Labbé, Raphaël Vacher, Joseph Rochford, Elisabeth Mocaër.   

Abstract

The aim of this study was to evaluate the efficacy of agomelatine (S 20098) to accelerate reversal of the neuroendocrinological, behavioural and cyclical changes seen in a transgenic mouse model of the neuroendocrine characteristics of depression. The effects of agomelatine were assessed in transgenic mice with low glucocorticoid receptor (GR) function, after acute stress or induced phase shift, and compared to desipramine and melatonin. Mice were injected 2 h before the onset of the dark period with agomelatine (10 mg/kg, i.p.), desipramine (10 mg/kg, i.p.), melatonin (10 mg/kg, i.p.) or vehicle (hydroxy-ethyl-cellulose (HEC) 1%) each day for 21 to 42 days. Agomelatine was effective in reversing the transgenic mouse behavioural changes noted in the Porsolt forced swim test as well as in the elevated plus maze. Both the number of open arm entries and the total time spent in open arms of the elevated plus maze is greatly increased in transgenic mice. The mean time spent in open arms is exquisitely sensitive to reversal by agomelatine and desipramine. Agomelatine also markedly accelerated readjustment of circadian cycles of temperature and activity following an induced phase shift. This action of agomelatine was superior to that of melatonin while desipramine was without effect. The accelerating effect of agomelatine was particularly notable if treatment was started 3 weeks prior to the induced phase shift. Agomelatine treatment did not cause any major change in corticosterone or adrenocorticotropic hormone (ACTH) concentrations nor in vasopressin (AVP), corticotropin-releasing hormone (CRH), GR and mineralocorticoid receptor (MR) mRNAs levels, which make it unlikely that the mechanism of agomelatine action is related to hypothalamic-pituitary-adrenocortical (HPA) axis changes. The present study shows that agomelatine displays some characteristics of antidepressant drug action in the transgenic mouse model, effects that could be partially related to its chronobiotic properties.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16005135     DOI: 10.1016/j.pnpbp.2005.04.032

Source DB:  PubMed          Journal:  Prog Neuropsychopharmacol Biol Psychiatry        ISSN: 0278-5846            Impact factor:   5.067


  21 in total

1.  Exogenous daytime melatonin modulates response of adolescent mice in a repeated unpredictable stress paradigm.

Authors:  Adejoke Yetunde Onaolapo; Ajibola Nurudeen Adebayo; Olakunle James Onaolapo
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2016-11-14       Impact factor: 3.000

Review 2.  Beyond the monoaminergic hypothesis: neuroplasticity and epigenetic changes in a transgenic mouse model of depression.

Authors:  Renaud Massart; Raymond Mongeau; Laurence Lanfumey
Journal:  Philos Trans R Soc Lond B Biol Sci       Date:  2012-09-05       Impact factor: 6.237

3.  Antidepressant- and anxiolytic effects of the novel melatonin agonist Neu-P11 in rodent models.

Authors:  Shao-wen Tian; Moshe Laudon; Li Han; Jun Gao; Fu-lian Huang; Yu-feng Yang; Hai-feng Deng
Journal:  Acta Pharmacol Sin       Date:  2010-06-28       Impact factor: 6.150

4.  Blockade of stress-induced increase of glutamate release in the rat prefrontal/frontal cortex by agomelatine involves synergy between melatonergic and 5-HT2C receptor-dependent pathways.

Authors:  Daniela Tardito; Marco Milanese; Tiziana Bonifacino; Laura Musazzi; Massimo Grilli; Alessandra Mallei; Elisabeth Mocaer; Cecilia Gabriel-Gracia; Giorgio Racagni; Maurizio Popoli; Giambattista Bonanno
Journal:  BMC Neurosci       Date:  2010-06-03       Impact factor: 3.288

Review 5.  Agomelatine, the first melatonergic antidepressant: discovery, characterization and development.

Authors:  Christian de Bodinat; Béatrice Guardiola-Lemaitre; Elisabeth Mocaër; Pierre Renard; Carmen Muñoz; Mark J Millan
Journal:  Nat Rev Drug Discov       Date:  2010-06-25       Impact factor: 84.694

6.  Agomelatine (S20098) modulates the expression of cytoskeletal microtubular proteins, synaptic markers and BDNF in the rat hippocampus, amygdala and PFC.

Authors:  Nataly Ladurelle; Cecilia Gabriel; Adela Viggiano; Elisabeth Mocaër; Etienne E Baulieu; Massimiliano Bianchi
Journal:  Psychopharmacology (Berl)       Date:  2011-12-08       Impact factor: 4.530

Review 7.  Agomelatine: mechanism of action and pharmacological profile in relation to antidepressant properties.

Authors:  B Guardiola-Lemaitre; C De Bodinat; P Delagrange; M J Millan; C Munoz; E Mocaër
Journal:  Br J Pharmacol       Date:  2014-08       Impact factor: 8.739

8.  Chronic agomelatine treatment corrects behavioral, cellular, and biochemical abnormalities induced by prenatal stress in rats.

Authors:  Sara Morley-Fletcher; Jerome Mairesse; Amelie Soumier; Mounira Banasr; Francesca Fagioli; Cecilia Gabriel; Elisabeth Mocaer; Annie Daszuta; Bruce McEwen; Ferdinando Nicoletti; Stefania Maccari
Journal:  Psychopharmacology (Berl)       Date:  2011-04-19       Impact factor: 4.530

9.  The novel antidepressant agomelatine normalizes hippocampal neuronal activity and promotes neurogenesis in chronically stressed rats.

Authors:  Girstaute Dagyte; Andrea Trentani; Folkert Postema; Paul G Luiten; Johan A Den Boer; Cecilia Gabriel; Elisabeth Mocaër; Peter Meerlo; Eddy A Van der Zee
Journal:  CNS Neurosci Ther       Date:  2010-03-11       Impact factor: 5.243

Review 10.  Agomelatine: a preliminary review of a new antidepressant.

Authors:  Michael Zupancic; Christian Guilleminault
Journal:  CNS Drugs       Date:  2006       Impact factor: 5.749

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.